A. Rejuvenating somatic cells to pluripotency.
Fetal cell fate is reversible chemically. We previously reprogrammed human fetal stem cells to functional pluripotency using valproic acid (VPA) and without genetic manipulation or ectopic expression of pluripotency factors (1) (2) (3) . Somatic cells can be reprogrammed into pluripotent stem cells, i.e. (7) . Manipulation of the environment, such as biophysical cues, can also modulate cell fate (8) . Similarly, chemicals, in particular small molecules, have been used to modulate reprogramming, either by increasing reprogramming efficiency, and/or to replace one or more transcription factors (9) . Several small molecule compounds involved in epigenetic regulation have been identified for their role in the reprogramming process either via somatic cell nuclear transfer (SCNT), or ectopic expression of a define set of transcription factors to replace one, or more, of the reprogramming factors. For example, it was shown that hyperacetylation improves reprogramming of somatic nuclei following nuclear transfer (10) and that the histone deacetylase inhibitor trichostatin A (TSA) reduces abnormal DNA hypermethylation following cloning by SCNT, thereby increasing success rate of mouse cloning via SCNT (11) . Similarly, the histone deacetylase inhibitor valproic acid improves reprogramming efficiency of mouse embryonic fibroblasts (MEF) without the introduction of c-Myc (12) and enables the reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2, without the need for the oncogenes c-Myc or Klf4 (13, 14) . Generally used for the treatment of epilepsy and bipolar disorder, VPA (2-propyl pentanoic acid) enhances OCT4 promoter activity via activation of the PI3K/Akt/mTOR pathway in mouse cells (15, 16) . VPA is involved in several regulatory mechanisms including GSK3b, Akt, ERK, phosphoinositol, tricarboxylic acidcycle, GABA, and OXPHOS pathways (17) .
Induced pluripotent stem cells, which can be generated from different tissues, have properties that differ according to their tissue of origin, because they maintain a unique residual DNA methylation that influences their 5 differentiation potential, i.e. "epigenetic memory of the donor tissue" (18) . In addition, the tissue of origin can also influence the efficiency and yield of reprogramming. For example, keratinocytes being reprogrammed more readily than fibroblasts (19, 20) , and fibroblasts isolated from different tissues vary in their reprogramming efficiency. In that context, stem cells, which are less lineage committed than terminally differentiated somatic cells, are easier to reprogram, and can be reprogrammed with a reduced number of factors, and adult neural stem cells can revert to functional pluripotency using OCT4 only (21) . In addition to the differentiation status of the tissue of origin, the development age of the parental population also influences the capacity of the cells to revert to an earlier state of pluripotency. For example, embryonic and fetal tissues can be reprogrammed with a higher efficiency than adult tissues, yielding iPS cells that are functionally most comparable to embryonic stem cells (18, 22, 23) . Of importance, the Ink4/Arf locus, which encodes p15(INK4b) , ARF, and p16(INK4a) genes in human chromosome 9p21, has been shown to be a barrier for iPS cell derivation, with the locus being silenced in both murine and human iPS and ES cells (22) 
D. Advantages and disadvantages of deriving iPS cells from fetal tissues
Cells isolated from fetal tissues can be used for both prenatal and perinatal autologous and allogeneic therapy. However, the isolation of fetal cells from fetal somatic tissues in the first trimester requires pregnancy termination, an obstacle to autologous applications. The harvest of fetal blood in continuing pregnancies is feasible, but technically challenging. One group has developed ultrasound-guided fetal blood sampling in ongoing pregnancies at risk of haemoglobinopathies with a loss rate of only 5% at gestations as early as 12 weeks (52). Thin-gauge embryo-fetoscopes also allow early fetal blood sampling from the umbilical cord under direct visualization (53) . Alternatively, amniotic fluid stem cells can be isolated during ongoing pregnancy from the surplus of amniocentesis, but this is not a prenatal diagnostic systematically performed. Most suitable fetal tissues include term placenta, which is discarded at birth and can be stored to isolate stem cells. We, and others, have shown that term placenta contains chorionic stem cells (CSC) with a similar phenotype to AFS cells (38) . 
E. iPS cells derived from fetal tissues for clinical applications
Generating iPS cells for clinical application aims at avoiding the potential risk of insertional mutagenesis associated with the random integration of the transgenes within the genome. Attempts to overcome this led to the development of excisable vectors, using Cre-recombinase to remove the integrated construct after reprogramming. However, each excision event leaves a small long terminal repeat fragment behind, which can still cause genotoxicity (58) (59) (60) ). An alternative is the piggyBac transposon system, where the transposase can be used after reprogramming to completely remove the transposon (61, 62) . Nevertheless, the efficiency of this system is low, and DNA sequencing is required to screen for any genetic modifications at the insertion sites, making this technology too laborious to be used in a clinical setting. Non-integrating systems were developed to overcome the pitfall of insertional mutagenesis and produce safer, clinically relevant iPS cells. These include both virus-based and virus-free approaches. Nonintegrating viral methods utilize adenovirus-or Sendai virus-based systems to transfect plasmids carrying the transgenes of interest (63) . However, these methods are hindered by even lower efficiency levels of around 0.001%, due to transient expression of the transgenes. Subsequently, another method used to achieve non-integrative transgene expression used episomal constructs (64) or mini-circle vectors (65, 66) Because pluripotent stem cells form teratomas in vivo, they must be differentiated into specific lineages of interest in vitro and selected for absence of pluripotency marker expression (for example by absence of CD24 expression using flow cytometry cell sorting) prior to being injected. However, the capacity of iPS cells to differentiate is regulated by the Germ Cell Nuclear Factor (GCNF) (Nuclear receptor subfamily 6 group A member 1, NR6a1), a silencer of pluripotency genes required for the repression of pluripotency genes during development and used as a marker to distinguish completely reprogrammed iPS cells from incompletely pluripotent cells (70) . Therefore, one of the challenges of using iPS cells for cell therapy is the ability to 
